Becton Dickinson (BDX) announced the first patient treated in an investigational device exemption clinical trial intended to advance BD’s efforts to achieve premarket approval from the FDA for the use of GalaFLEX Lite Scaffold in decreasing capsular contracture recurrence during breast revision surgery.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Tariff delay positive for Mexico-exposed medtech companies, says BofA
- Becton Dickinson recalls one lot of ChloraPrep Clear 1 mL applicators
- Becton Dickinson’s Hold Rating: Balancing Strong Financials with Strategic Uncertainty
- Becton Dickinson price target raised to $279 from $278 at Barclays
- Becton Dickinson director buys $350.4K in common stock